Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Baidu Inc (BIDU) Price & Performance

ACADIA Pharmaceuticals Inc.Trade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs Baidu Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.56 (market cap $5.07B), while Baidu Inc trades at $104.4 (market cap $36.18B). The key difference: Baidu Inc is far larger — about 7.1× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Baidu Inc nearer its low. Which is the better fit depends on your goals.

ACADBIDU
Market Cap
$5.07B$36.18B
Sector
HealthMedia
52-Week High
$29.41$162.52
52-Week Low
$20.06$86.76
Enterprise Value
$4.19B$32.81B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.

The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.

Baidu Inc

Baidu (BIDU) trades at $103.7, down 5.3% in the last session, reflecting bearish technical signals and recent earnings volatility. The stock shows weak profitability with a net margin of 1.02% and elevated P/E of 78.19, though it trades below book value. Recent news highlights autonomous vehicle testing in London and an upcoming Q2 2026 earnings report on August 18, 2026 (PRNewsWire, 2026-07-31).

Outlook is mixed: strong analyst buy consensus (75.47%) and a $169.80 price target suggest upside, but declining revenue, negative cash flows, and China market risks pose headwinds. AI initiatives offer growth potential, but investors face execution and macroeconomic uncertainties.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Read more on ACAD

About Baidu Inc

Baidu, Inc. operates an Internet search engine. The Company offers algorithmic search, enterprise search, news, MP3, and image searches, voice assistance, online storage, and navigation services. Baidu serves clients globally.

Read more on BIDU